Avastin Receives New FDA Indication

On November 14, 2014, Avastin® (bevacizumab) solution for intravenous infusion was approved by the FDA in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. 

Click Here to Access Practice Information from Genentech.

Click Here to read the entire prescribing information.

FDA Approves a New Indication for XTANDI® (enzalutamide) capsules

Astellas Pharma US, Inc. is pleased to announce that the US Food and Drug Administration (FDA) has approved a new indication for XTANDI, an androgen receptor inhibitor. XTANDI is now indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

Please click here for Full Prescribing Information.

 

Velcade Receives New FDA Approval

Millennium: The Takeda Oncology Company is pleased to announce that VELCADE in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) is now approved for patients with previously untreated MCL. VR-CAP is the first and only FDA-approved regimen for the treatment of patients with previously untreated MCL. 

Click Here to read the announcement from Millennium. 

Click Here for full prescribing information.

 

FDA Approves a New Indication for XTANDI®

Astellas Pharma US, Inc. is pleased to announce that the US Food and Drug Administration (FDA) has approved a new indication for XTANDI, an androgen receptor inhibitor. XTANDI is now indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).1

For more information and to read the Safety Information go to www.xtandihcp.com   click here to view Full Prescribing Information.

MedImmune Metastatic Breast Cancer Campaign

More than 173,000 women in the United States are living with metastatic breast cancer (MBC), and each has a story to tell. Women with MBC encounter unique challenges, and it is often an important part of their journey to share their stories and connect with others who are living with the disease.

In support of women living with MBC, the MedImmune Specialty Care Division of AstraZeneca recently launched the #MBCStrength photo-sharing campaign. Women with MBC are encouraged to take photos of themselves that highlight their personal journeys and post them on Twitter with the hashtag #MBCStrength. Photos posted through October will be considered for a display in Times Square in New York City on October 13, 2014, Metastatic Breast Cancer Awareness Day.

For more information about the #MBCStrength photo-sharing campaign, visit www.MyMBCStory.com, a site that houses tools and information tailored for women living with MBC. New to the site are personal MBC accounts from Priscilla and Linda: two inspiring women who draw love and support from their family, friends and community.

FDA Approval for Keytruda

WHITEHOUSE STATION, N.J., Sept. 04, 2014 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 

Click Here to read the entire press release

Click Here to read the prescribing information

Click Here to read the announcement letter
 
Click Here for information on the Keytruda Access Program 

New FDA Approval for IMBRUVICA

SUNNYVALE, CA, July 28, 2014 -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted IMBRUVICA® (ibrutinib) regular (full) approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17 (del 17p CLL), including treatment naïve and previously treated del 17p CLL patients. 

Click Here to read the press release from Pharmacyclics. 

Click Here for the prescribing information.

Important Update from Noridian on Claims for Xoifigo

On July 16, 2014 Noridian posted the following important notice regarding claims for Xoifigo:


Claims with a date of service of September 1, 2014 or after, Noridian will begin requiring submission of the invoice price for payment for Radium 223 (Xoifigo). This radiopharmaceutical should be billed with A9699 when billing from the Medicare Physician Fee Schedule on a CMS-1500 Claim Form or electronically.

Providers must enter the name and dose of the radiopharmaceutical along with the invoice price in Item 19 of the CMS-1500 Claim Form or the electronic equivalent. Claims without this information will be denied as unprocessable.

Click Here to access this notice on the Noridian Website.